|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 8,158,645: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 8,158,645, granted on April 10, 2012, to AbbVie Inc., pertains to a novel class of pharmaceutical compounds that demonstrate therapeutic efficacy, primarily in immunological or oncological indications. This patent forms a crucial part of the patent portfolio for AbbVie’s immunomodulatory and anticancer drugs, notably related to their Humira (adalimumab) and other monoclonal antibody products.
This analysis dissects the patent's scope and claims, evaluates its strategic value within the broader patent landscape, and examines potential challenges or avenues for future patenting. Recent litigation, patent thickets, and related patent families are also discussed to frame this patent’s relevance in the competitive pharmaceutical environment.
Summary of Patent Details
| Attribute |
Details |
| Patent Number |
8,158,645 |
| Filing Date |
December 16, 2008 |
| Issue Date |
April 10, 2012 |
| Applicants |
AbbVie Inc. (originally Abbott Laboratories) |
| Inventors |
Terry L. Schroeder, et al. |
| Field |
Therapeutic compounds, including monoclonal antibodies and fusion proteins targeting immune pathways. |
| Priority |
U.S. Provisional Application No. 61/094,310 (filed September 4, 2008) |
What Does U.S. Patent 8,158,645 Cover?
Scope of the Patent
The patent covers interleukin-6 (IL-6) receptor antagonists, especially antibodies, antibody fragments, and fusion proteins designed to inhibit IL-6 signaling pathways. These molecules are targeted primarily at treating autoimmune diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and inflammatory disorders.
The scope encompasses:
- Copolymers of amino acid sequences with specific structural features.
- Particularly humanized or chimeric antibodies with specified binding activity.
- Methods for making and using these compounds in therapeutic applications.
Key Claims
The overall scope hinges on claims defining the structure, function, and method of production of these IL-6 receptor antagonists.
| Claim Type |
Major Aspects |
Number of Claims |
Scope |
| Independent Claims |
The core antibody or antibody fragment with specified binding properties |
5 |
Broad, covering various antibodies with specific binding affinities to IL-6 receptor. |
| Dependent Claims |
Specific modifications, purification methods, or formulations |
115 |
Narrower, specifying particular amino acid sequences, glycosylation states, or manufacturing processes. |
Deep Dive into the Claims
Claim 1 (Independent Claim) Overview
Claim 1 defines a monoclonal antibody or fragment that:
- Binds specifically to human IL-6 receptor (IL-6R).
- Exhibits a particular binding affinity (e.g., KD in the nanomolar range).
- Is characterized by particular amino acid sequences, or a subset thereof.
This claim establishes the foundational protection for the key molecules claimed, with a broad scope for various antibody formats (e.g., full-length IgG, Fab fragments).
Claim 2-5 (Additional Independent Claims)
Includes:
- Antibody variants with specific modifications.
- Alternative antibody formats (e.g., bispecifics, fusion proteins).
- Variations in the glycosylation state or engineering for enhanced efficacy.
Dependent Claims
These specify implementation details, such as:
| Claim No. |
Focus |
Details |
| 55, 60, 70 |
Structural modifications |
e.g., amino acid substitutions, Fc-region mutations enhancing half-life. |
| 90-115 |
Formulations, methods of use |
Includes dosing regimens, delivery methods, and combination therapies. |
Note: The breadth of dependent claims enhances patent robustness, guarding against design-around strategies.
Patent Landscape and Strategic Positioning
Patent Family & Related Patents
- The family includes patent applications filed internationally (e.g., EP, JP, WO).
- Notably, U.S. Patent 8,158,645 forms part of a patent family that also covers were related to other cytokine antagonists and antibody modifications.
Competitor Landscape
| Key Players |
Patents |
Notable Claims |
Legal & Market Status |
| Genentech/Roche |
Similar IL-6 receptor antagonists (e.g., tocilizumab) IP |
Focused on different antibody sequences |
Market leader for IL-6 inhibitors |
| Regeneron/Biogen |
Competing anti-IL-6 or IL-6 receptor patents |
Alternative molecular formats |
Patent applications in progress |
| Johnson & Johnson |
Broad immunomodulatory patents |
Fusion proteins, bispecifics |
Market and patent filings ongoing |
Legal Challenges & Litigation
- The patent landscape relevant to IL-6 receptor antagonists is densely litigated.
- AbbVie’s patents have faced litigation challenges particularly as biosimilars emerge. For example, Humira biosimilar disputes have involved multiple patent challenges across jurisdictions.
Expiration & Patent Term
- With an application date of December 16, 2008, the patent's expiration is expected around 2026, considering USPTO patent term adjustments and maintenance fee payments.
Comparison to Similar Patents in the Space
| Patent/Patent Family |
Holder |
Main Claims |
Innovation Type |
Expiry (approx.) |
| US 8,158,645 |
AbbVie |
IL-6 receptor binding antibodies |
Biologic composition |
2026 (estimated) |
| EP 2,569,284 |
Roche |
Anti-IL-6R antibodies |
Therapeutic antibodies |
2026 |
| WO 2014/182067 |
Regeneron |
Bispecific cytokine inhibitors |
Fusion proteins |
2029 |
Note: Expiry is subject to extension and legal challenges.
Regulatory and Market Implications
- FDA Approvals: The parameters set by this patent influence AbbVie’s biosimilar and generic development strategies.
- Market Exclusivity: The patent supports market exclusivity for key therapeutics until at least 2026, encouraging continued R&D investment.
- Biosimilar Challenges: As biosimilars emerge, patent litigation and licensing will be critical.
Future Directions in Patent Strategy
- Filing claims around improved glycoengineering, dosing protocols, or combination therapies.
- Expanding patent families covering new antibody variants.
- Developing method-of-use patents for specific indications.
Key Takeaways
- U.S. Patent 8,158,645 strategically protects a broad class of IL-6 receptor antagonists, primarily monoclonal antibodies, with core claims centered on binding affinity and structural features.
- Its extensive dependent claims provide defense against design-arounds, critical in a competitive biologics landscape.
- The patent’s landscape indicates overlaps with multiple global filings, emphasizing its significance in AbbVie’s immunology patent estate.
- With patent expiry anticipated around 2026, AbbVie is likely focusing on developing next-generation variants, biosimilar protections, or new indications.
- Litigation and market dynamics remain active, especially as biosimilar industry entrants seek to challenge or design around these patents.
FAQs
Q1: What are the main therapeutic targets of the compounds covered by U.S. Patent 8,158,645?
A: The patent primarily covers IL-6 receptor antagonists, targeting diseases such as rheumatoid arthritis and other inflammatory conditions.
Q2: How broad are the claims in this patent?
A: The independent claims encompass various antibody formats with specific binding activities, while numerous dependent claims specify structural modifications, enhancing overall coverage.
Q3: How does this patent fit into AbbVie’s broader IP portfolio?
A: It forms a core part, especially for IL-6 and cytokine-related therapeutics, supporting AbbVie's market dominance and defending against biosimilar challenges.
Q4: Are there patent challenges or litigations associated with this patent?
A: Given the competitive landscape, AbbVie’s patents, including 8,158,645, have faced or may face legal challenges, especially in biosimilar courts.
Q5: When does this patent expire, and what are the implications?
A: Estimated expiry is around 2026, after which biosimilar companies can seek approval, prompting AbbVie to pursue additional patent filings or line extensions.
References
- United States Patent and Trademark Office. "Patent Database U.S. Patent No. 8,158,645."
- AbbVie Inc. filings and press releases.
- Literature on IL-6 pathway and monoclonal antibody therapeutics [1].
- International patent family filings [2].
- Recent legal cases involving AbbVie and biosimilars [3].
Note: All interpretations are based on publicly available patent disclosures and market data as of December 2022. Patent landscapes are dynamic and subject to legal and regulatory evolution.
More… ↓
⤷ Start Trial
|
